Hans Scham is a leading brand in the field of biotechnology, specializing in the development of galectin and LOXL2 modulators for the treatment of severe diseases. With a focus on fibrosis, inflammation, and cancer, we are dedicated to creating novel small molecule therapeutics that target these biological pathways. Founded by renowned fibrosis-focused scientists and biotech executives, Hans Scham has over 10 years of research experience in galectin and fibrosis modulators.

Our team possesses in-depth knowledge of the galectin family of proteins and the LOXL2 enzyme, understanding how they influence various biological pathways in complex diseases. Our goal is to develop a portfolio of drugs that target the underlying pathways of fibrosis to benefit patients suffering from a wide range of fibrotic diseases. We are currently focusing on galectin-3 and LOXL2, which play crucial roles in the development of tissue scarring, inflammation, and cancer.

With a strong foundation in scientific exploration, Hans Scham is at the forefront of innovative therapies, offering new treatment possibilities for severe diseases